Pharma multinationals move to stop generic drug registration prior to originator's patent lapse in Russia

Global drugmakers operating in Russia have called on the country’s government to impose a ban on the registration of generics before the expiration of the patent protection of original drugs.

The companies believe that the early registration of generics leads to a breakdown of state tenders for the purchase of drugs for domestic requirements, reports The Pharma Letter’s local correspondent.

According to a spokesman of the Association of International Pharmaceutical Manufacturers in Russia (AIPM), local hospitals may experience interruptions to drug supplies, as the auctions may involve participation of those manufacturers whose drugs, according to the current Russian legislation, are positioned as counterfeit.